Results 41 to 50 of about 14,520 (202)
, 2021 Introduction: Fulvestrant has demonstrated efficacy in hormone receptor positive (HR+) metastatic breast cancer (mBC), both in first-and second-line settings. In clinical practice, however, fulvestrant has been used as a later-line therapy.
Duc Le +9 more
core +1 more source
Development and validation of a gene expression score that predicts response to fulvestrant in breast cancer patients. [PDF]
PLoS ONE, 2014 Fulvestrant is a selective estrogen receptor antagonist. Based on the measured growth inhibition of 60 human cancer cell lines (NCI60) in the presence of fulvestrant, as well as the baseline gene expression of the 60 cell lines, a gene expression score ...
Steen Knudsen +7 more
doaj +1 more source
Journal of Diabetes Investigation, EarlyView.Continuous glucose monitoring (CGM) visualized cyclic glycemic fluctuations associated with the 4‐days‐on/3‐days‐off capivasertib schedule. Compared with off‐treatment days, dosing days showed higher mean sensor glucose, greater coefficient of variation (CV), more time above 250 mg/dL, and lower time in range (TIR; 70–180 mg/dL).
Hiroki Okumura +13 more
wiley +1 more source
Fulvestrant inhibits DU145 cell growth, migration, and invasion.
, 2014 (A) Fulvestrant induces growth inhibition of DU145 cells via an ERβ-dependent mechanism. Growth of the fulvestrant-treated DU145 cells with or without ERβ siRNA knockdown for 4 days relative to the ethanol-treated control cells with negative-control ...
Queeny Kwan-Yi Chan (565317) +8 more
core +1 more source
Therapeutic Advances in Medical Oncology, 2017 We reviewed randomized phase II/III trials comparing first- or second-line endocrine therapy as monotherapy or in combination with targeted therapies for treatment of postmenopausal patients with hormone receptor-positive advanced breast cancer.
Tomás Reinert, Carlos H. Barrios
doaj +1 more source
Phase II trial of fulvestrant plus enzalutamide in ER+/HER2− advanced breast cancer
npj Breast Cancer, 2023 This clinical trial combined fulvestrant with the anti-androgen enzalutamide in women with metastatic ER+/HER2− breast cancer (BC). Eligible patients were women with ECOG 0–2, ER+/HER2− measurable or evaluable metastatic BC. Prior fulvestrant was allowed.
Anthony D. Elias +22 more
doaj +1 more source
Frontiers in Oncology, 2022 The prognosis for female patients with locoregionally recurrent breast cancer has improved with the concurrent local and systemic treatment under multiple disciplinary teams.
Jingxian Ding, Yali Cao, Yonghong Guo
doaj +1 more source
Long‐term benefit from adjuvant tamoxifen therapy for ER+ HER2− breast cancer by PR positivity
International Journal of Cancer, Volume 159, Issue 2, Page 450-459, 15 July 2026.What's new? Tamoxifen is a cornerstone of endocrine therapy for estrogen receptor (ER)‐positive/human epidermal growth factor receptor 2 (HER2)‐negative breast cancer. Its long‐term benefits, however, may vary by progesterone receptor (PR) status. Here, using data from the Stockholm tamoxifen trials, the authors evaluated whether PR expression predicts
Anna E. Nordenskjöld +8 more
wiley +1 more source
Frontiers in Oncology, 2023 AimTo evaluate the cost-effectiveness of palbociclib plus fulvestrant in the second-line treatment of women with hormone receptor-positive and human epidermal growth factor receptor 2-negative advanced breast cancer based on the latest published follow ...
Wentao Zhu +6 more
doaj +1 more source
International Journal of Cancer, Volume 159, Issue 2, Page 460-466, 15 July 2026.What's new? While the effectiveness of systemic anticancer therapy is well documented, it commonly causes severe toxicity. This study of the 467 systemic anticancer therapy agents currently approved globally for clinical and/or research purposes found that peripheral neurotoxicity is associated with 45% of classical chemotherapies, 21% of targeted ...
Cassie Higgins +3 more
wiley +1 more source